We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Illumina

Illumina develops, manufactures and markets integrated systems for the analysis of genetic variations and biological ... read more Featured Products: More products

Download Mobile App




Genetic Findings Explain Inherited Predisposition to Myeloma

By LabMedica International staff writers
Posted on 21 Jul 2016
Multiple myeloma (MM) is a malignancy of plasma cells that has a significant genetic component as evidenced by the two- to four-fold increased risk shown in relatives of MM patients.

Every year around 5,500 people in the UK are diagnosed with myeloma, a rare and incurable form of cancer affecting the plasma cells in bone marrow, and around one in 115 men and one in 155 women in the general population will develop myeloma in their life time.

A large team of international scientists led by those at The Institute of Cancer Research (London, UK) have identified eight new genetic variations in the human genome that could be linked to an increased risk of developing myeloma. More...
The teams compared the genomes of myeloma patients with those of healthy individuals. The team also combined and re-analyzed data from similar research undertaken as part of a genome-wide association study (GWAS). In total, the researchers compared DNA from 9,866 myeloma patients with 239,188 healthy adults.

DNA was extracted from venous blood samples and genotyped in some countries using Illumina Human OmniExpress-12 v1.0 arrays (Illumina, San Diego, USA). Each country’s team used the most appropriate microarray for their part of the study. Eight single nucleotide polymorphisms (SNPs), inherited single letter variations in DNA, were linked to increased susceptibility of developing myeloma. These SNPs were located in regions of the genome involved in regulating genes linked to cell processes known to go wrong in myeloma development. These included the production of antibodies in plasma cells, as well as the regulation of gene activity and the maturation of these cells.

In total 17 risk variants for myeloma have now been identified by the scientists. It is estimated that the risk variants identified so far account for just 20% of the heritable risk factors connected to myeloma and further GWAS studies of patients are planned. The authors suggest that subtle effects on the activity of key genes could mean that the proper development of plasma cells breaks down, increasing the likelihood of developing myeloma.

Richard Houlston, MD, PhD, a Professor of Molecular and Population Genetics and study leader, said, “Our study expands our understanding of how inherited risk factors can influence the risk of myeloma. We know that the inherited risk of myeloma does not come from just one or two major risk genes, as can be the case with breast cancer, but from multiple different genetic variants, each with only a small individual effect on risk. Identifying more of these variants gives us new insights into the potential causes of the disease, and open up new strategies for prevention.” The study was published on July 1, 2016, in the journal Nature Communications.

Related Links:
The Institute of Cancer Research
Illumina


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
hCG Whole Blood Pregnancy Test
VEDALAB hCG-CHECK-1
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.